Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

2021604 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 398, Issue 10313, pp. 1811-1824

Field-Weighted Citation Impact: 61.19